You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
An automated system for post-surgical health and environmental monitoring with real-time alerts for laboratory rodents using scalable hardware and deep learning
SBC: APPLIED UNIVERSAL DYNAMICS, CORP Topic: ODAbstract This proposal responds directly to the PAR-21-225 Novel Tools and Devices for Animal Research Facilities and to Support Care of Animal Models. While it is standard practice to continuously monitor the health of human patients following a major surgery, this is typically not the case for monitoring recovery in rodent pre- clinical research. For example, it is common practice that rats and ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a novel personalized medicine platform using apheretically isolated circulating tumor cells to assess drug responsiveness in prostate cancer
SBC: ASTRIN BIOSCIENCES, INC. Topic: 102Project Summary Metastatic prostate cancer is a notoriously heterogeneous disease that is difficult to treat. The five-year survival rate has not improved over the past twenty-five years and the median survival rate for those diagnosed with metastatic castration resistant prostate cancer (mCRPC) is only 15-36 months. Precision medicine has the potential to improve mCRPC outcomes. Transciptomic seq ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Non-catalytic FAK inhibitors as novel therapeutics for lung fibrosis
SBC: Faknostics, LLC Topic: NHLBIPROJECT ABSTRACT Idiopathic pulmonary fibrosis (IPF) is a relentlessly progressive and fatal fibrotic lung disorder which disproportionately affects men and the elderly. Although two drugs (pirfenidone and nintedanib) have recently gained FDA-approval for IPF and progressive fibrosing lung disorders related to connective tissue diseases (rheumatoid arthritis and scleroderma, more common in younger ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Improving Patient Care Through Objective Monitoring of At-Home Repetitive Ritual Behaviors in Obsessive-Compulsive Disorder
SBC: ADVANCED MEDICAL ELECTRONICS CORP Topic: 104Project Summary Obsessive-compulsive disorder (OCD) is characterized by intrusive, distressing thoughts (obsessions) in response to which an individual feels compelled to perform a repetitive behavior (compulsions), which are performed in order to reduce the acute distress experienced by the patient but which perpetuate OCD symptoms. Effective treatment requires accurate reporting of compulsive be ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Profiling circulating metabolites for the diagnosis of pulmonary hypertension
SBC: Metfora LLC Topic: NHLBIPulmonary arterial hypertension (PAH) is a progressive and fatal disease. Initially, PAH develops asymptomatically or with mild symptoms that are often unrecognized by primary doctors. However, even after the onset of non-specific symptoms, such as dyspnea on exertion and fatigue, PAH remains unrecognized for ≥two years. On average, it takes a patient five visits to a general practitioner, and t ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
A capsule-based bioconjugate vaccine to prevent Klebsiella pneumoniae infections
SBC: VaxNewMO Topic: NIAIDPROJECT SUMMARY Klebsiella pneumoniae is an encapsulated human pathogen capable of causing a myriad of human infections. Recently, K. pneumoniae has also emerged as one the most common causes of secondary bacterial pneumonia in COVID-19 patients. Over the last 40 years, K. pneumoniae has evolved into two distinct pathotypes, known as classical K. pneumoniae (cKp) and hypervirulent K. pneumoniae (h ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Targeting the P Selectin Pathway to Improve ARDS Survival
SBC: AQUALUNG THERAPEUTICS, CORP Topic: NHLBIABSTRACT Acute respiratory distress syndrome (ARDS) is a critical illness with 30- 40% mortality and currently there are no FDA-approved therapies. Quell Pharma and Aqualung Therapeutics have developed a recombinant soluble, cell-free form of recombinant human P-selectin glycoprotein ligand-1 (PSGL-1) designated Tandem P-Selectin glycoprotein ligand-1 immunoglobulin (TSGL-Ig), which is a potent pa ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Development of lysosome targeted therapeutics
SBC: MAJESTIC THERAPEUTICS, LLC Topic: 102Project Summary/Abstract Lysosomal proteolysis facilitates the turnover of organelles and selected long-lived proteins and is a critical regulator of cellular homeostasis. Its aberrant activation promotes drug resistance and cancer progression by generating alternative sources of survival sustaining metabolic fuel to cells that are stressed by hypoxia, radiation, chemotherapy, and targeted agents. ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
Development of a Pre-Exposure Vaccine for Population-Level ProtectionAgainst Staphylococcus aureus Infection
SBC: FORWARD DEFENSE, LLC Topic: NIAIDPROJECT SUMMARY Staphylococcus aureus is an aggressive antibiotic-resistant human bacterial pathogen. S. aureus is a leading cause of infectious disease morbidity, mortality, and hospital-associated infection in the U.S., and a formidable health threat worldwide. Given the rapid acquisition of drug resistance by S. aureus, universal vaccination has been a premier goal in the field to provide a dur ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health -
App-Assisted Day Reconstruction to Reduce Treatment Burden and Logistic Toxicity in Cancer Patients
SBC: Daynamica Inc. Topic: NCIPROJECT SUMMARY Each year, more than 1.7 million new cancer patients in the U.S. undergo intense, multimodal treatments that that create numerous logistical challenges in managing treatment and everyday life priorities. In the current cancer care system, “logistic toxicity”—the toxic effects imposed by the logistical burden of carrying out cancer treatment-related tasks on patient well-being ...
STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health